The multi-site CiPA Phase II Myocyte Validation report by Blinova et al. is now available!
We are delighted that the results of this study validate the use of Ncardia's Cor.4U® cardiomyocytes for regulatory safety pharmacology.
- 28 drugs classified by Torsades-proarrhythmic risk studied in blinded experiments.
- Two commercial human cardiomyocyte lines used with 5 devices across 10 sites.
- Repolarization effects evaluated using microelectrode array & voltage-sensing dyes.
- Statistical model predicted proarrhythmic risk from electrophysiologic responses.
Stefan Braam, Ncardia CEO, said: "This is a landmark paper. It is probably one of the most extensive cardiac safety pharmacology validation studies ever performed and definitely a key milestone in the history of iPSC technology..."
For more information and to read the Validation Study please visit our CiPA landing page.